Redhill Historical Income Statement
| RDHL Stock | USD 7.96 0.05 0.63% |
Historical analysis of Redhill Biopharma income statement accounts such as Operating Income of 13.3 M, Ebit of 25.5 M, Research Development of 3.3 M or Ebitda of 27.6 M can show how well Redhill Biopharma performed in making a profits. Evaluating Redhill Biopharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Redhill Biopharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Redhill Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Redhill Biopharma is a good buy for the upcoming year.
Redhill |
About Redhill Income Statement Analysis
Redhill Biopharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Redhill Biopharma shareholders. The income statement also shows Redhill investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Redhill Biopharma Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Redhill Biopharma. It is also known as Redhill Biopharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Revenue
Total revenue comprises all receipts Redhill Biopharma generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Most accounts from Redhill Biopharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Redhill Biopharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.At this time, Redhill Biopharma's Total Other Income Expense Net is quite stable compared to the past year. Net Income is expected to rise to about 25.1 M this year, although the value of Selling General Administrative will most likely fall to about 18.4 M.
Redhill Biopharma income statement Correlations
Click cells to compare fundamentals
Redhill Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Redhill Biopharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 171.9K | 8.8M | 18.2M | 8.1M | 2.0M | 3.0M | |
| Interest Expense | 438K | 12.8M | 16.6M | 41.3M | 367K | 348.7K | |
| Selling General Administrative | 11.5M | 25.4M | 76.6M | 55.0M | 28.9M | 18.4M | |
| Other Operating Expenses | 49.5M | 128.0M | 166.9M | 104.6M | 6.1M | 5.8M | |
| Operating Income | (43.2M) | (63.7M) | (81.1M) | (42.8M) | 12.6M | 13.3M | |
| Ebit | (40.8M) | (63.7M) | (81.2M) | (51.0M) | 24.3M | 25.5M | |
| Research Development | 17.4M | 16.5M | 29.5M | 7.3M | 3.5M | 3.3M | |
| Ebitda | (40.7M) | (54.9M) | (63.0M) | (42.8M) | 26.3M | 27.6M | |
| Total Operating Expenses | 47.2M | 91.2M | 117.5M | 71.3M | (9.6M) | (9.1M) | |
| Income Before Tax | (42.3M) | (76.2M) | (97.7M) | (71.7M) | 24.0M | 25.1M | |
| Total Other Income Expense Net | 897K | (12.5M) | (16.6M) | (28.8M) | 11.3M | 11.9M | |
| Net Income | (43.6M) | (89.0M) | (114.3M) | (59.2M) | 23.9M | 25.1M | |
| Income Tax Expense | 1.3M | 12.8M | 16.6M | (12.4M) | (2.0) | (1.9) | |
| Total Revenue | 6.3M | 64.4M | 85.8M | 61.8M | 6.5M | 6.2M | |
| Gross Profit | 4.0M | 27.5M | 36.4M | 28.5M | 3.1M | 5.1M | |
| Cost Of Revenue | 2.3M | 36.9M | 49.4M | 33.3M | 3.5M | 3.3M | |
| Net Income From Continuing Ops | (42.3M) | (76.2M) | (97.7M) | (71.7M) | 23.9M | 25.1M | |
| Net Income Applicable To Common Shares | (38.8M) | (42.3M) | (76.2M) | (97.7M) | (88.0M) | (83.6M) | |
| Net Interest Income | 5K | (12.6M) | (16.6M) | (41.2M) | (2.2M) | (2.3M) | |
| Interest Income | 443K | 176K | 51K | 140K | 94K | 176.2K | |
| Selling And Marketing Expenses | 18.3M | 49.3M | 11.4M | 9.1M | 2.1M | 2.0M | |
| Reconciled Depreciation | 1.2M | 8.7M | 18.1M | 8.2M | 2.0M | 1.9M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (302.63) | Revenue Per Share 4.733 | Quarterly Revenue Growth (0.28) | Return On Assets (0.45) | Return On Equity (17.09) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.